The leading Ex vivo screening platform for blood cancer therapeutics, showcasing the most extensive collection of rare, clinically significant blood cancer models, including AML, ALL, CLL, MCL, MDS, and MM.
Enrolling only until December 16th, 2024
Transform Your Blood Cancer Research with Our Extensive Bank
Advance your blood cancer research by leveraging the largest bank of extremely difficult-to-source, never-passaged primary models of hematological malignancies, featuring models of Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM), and Myelodysplastic Syndrome (MDS). These clinically relevant models offer heterogeneous responses, mirroring those observed in patients, ensuring dependable outcomes crucial for advancing your drug discovery efforts with confidence.
Clinically Relevant Models
Bank of 81 primary patient blood cancer models that correlate with clinical outcomes
Industry's Largest Bank
Includes models representing major blood cancers including AML, ALL, CLL, MCL, MM, & MDS
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and clinical responses
Features the industry's largest bank of deeply characterized models:
30 primary models of Acute Myeloid Leukemia (AML)
6 primary models of T-cell Acute Lymphoblastic Leukemia (T-ALL)
8 primary models of B-cell Acute Lymphoblastic Leukemia (B-ALL)
10 primary models of Chronic Lymphocytic Leukemia (CLL)
8 primary models of Mantle Cell Lymphoma (MCL)
5 primary models of Multiple Myeloma (MM)
6 primary models of Myelodysplastic Syndrome (MDS)
